AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27856951
Drug: Elevated Lp(a)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated Lp(a) levels (>30 mg/dL)
Trial: 27856951
Drug: Normal Lp(a)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Lp(a) levels (≤30 mg/dL)
Trial: 27857630
Drug: Action Observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action Observation Therapy (AOT) in addition to conventional physical therapy
Trial: 27857630
Drug: Written information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Written information in addition to conventional physical therapy
Trial: 27860160
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 1 week
Trial: 27861509
Drug: Azithromycin-Chloroquine (AZCQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Azithromycin-Chloroquine (AZCQ) 250/155 mg, single 3-day course
Trial: 27863192
Drug: Induction chemotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction chemotherapy, dose-escalated hyperfractionated craniospinal radiotherapy, and maintenance chemotherapy
Trial: 27863194
Drug: Pomalidomide 5
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide 5 mg once per day for 21 days per 28-day cycle
Trial: 27863197
Drug: Pembrolizumab 10
RxNorm normalized name: pembrolizumab 100 MG in 4 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab 10 mg/kg once every 2 weeks or once every 3 weeks, or 2 mg/kg once every 3 weeks
Trial: 27863522
Drug: Prescribed antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribed antipsychotic medication regimens (including types, combinations, and Daily Defined Dose equivalent)
Trial: 27863522
Drug: Antipsychotic polypharmacy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic polypharmacy and higher doses of antipsychotics
Trial: 27864641
Drug: Anodized tapered
RxNorm normalized name: calcium iodized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anodized tapered implants with a conical connection and integrated platform shifting
Trial: 27865764
Drug: rAAV.sFLT-1 gene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rAAV.sFLT-1 gene therapy
Trial: 27865764
Drug: ranibizumab injections
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ranibizumab injections (control)
Trial: 28774338
Drug: nab-paclitaxel 125
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: nab-paclitaxel 125 mg/m²
Trial: 27866695
Drug: Oral formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral formulations of antipsychotics (including risperidone, olanzapine, aripiprazole, zuclopenthixol, fluphenazine, and haloperidol)
Trial: 27870734
Drug: Preoperative copeptin
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative copeptin (≥9.6 pmol/L)
Trial: 27871319
Drug: PEP02 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP02 (irinotecan liposome injection) at 80 mg/m²
Trial: 27871319
Drug: PEP02 (irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEP02 (irinotecan liposome injection) in combination with 5-FU and LV
Trial: 27872037
Drug: Internet-based delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based delivery of 6 evidence-based health promotion programs (sexual health, hearing loss, alcohol use, tobacco use, drug use, nutrition and physical activity)
Trial: 27872060
Drug: Bortezomib alone
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib alone (1.3 mg/m2)
Trial: 27872070
Drug: Cipargamin 30
RxNorm normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin 30 mg
Trial: 27872070
Drug: Cipargamin 20
RxNorm normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin 20 mg
Trial: 27872070
Drug: Cipargamin 10
RxNorm normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin 10 mg
Trial: 27872070
Drug: Cipargamin 15
RxNorm normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin 15 mg
Trial: 27872070
Drug: Cipargamin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cipargamin (all doses)
Trial: 27872115
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) performed at 18-20 gestational weeks (early OGTT)
Trial: 27872115
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose tolerance test (OGTT) performed at 24-28 gestational weeks (regular OGTT)
Trial: 27872130
Drug: Ipatasertib (GDC-0068),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipatasertib (GDC-0068), 200 mg daily or more
Trial: 27872236
Drug: RO6836191 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6836191 (single doses)
Trial: 27872236
Drug: RO6836191 (repeat-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO6836191 (repeat-dose toxicity studies)
Trial: 27875519
Drug: Somatostatin receptor
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin receptor expression measured on circulating tumour cells (CTCs) using CellSearch and immunohistochemistry on matched tissue samples.
Trial: 27876675
Drug: Trametinib plus
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Trametinib plus docetaxel (2.0 mg once daily, 75 mg/m2 docetaxel)
Trial: 27878356
Drug: Intravenous triapine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous triapine (48-96 mg/m) in combination with cisplatin chemotherapy
Trial: 27878356
Drug: Intravenous triapine
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous triapine (48-96 mg/m)
Trial: 27878474
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of warfarin
Trial: 27878567
Drug: Peficitinib 150
RxNorm normalized name: peficitinib
DrugBank: Peficitinib (DB11708)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Peficitinib 150 mg daily for 9 days
Trial: 27878567
Drug: Rosuvastatin 10
RxNorm normalized name: rosuvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 10 mg on days 1 and 10
Trial: 27878619
Drug: Activated carbon
RxNorm normalized name: Activated carbon
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated carbon applied locally into the rectum twice daily for 8 weeks
Trial: 27878892
Drug: SIGLEC9 polymorphisms
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIGLEC9 polymorphisms (specifically the G allele of rs2075803 and rs2075803 G/rs2258983 A haplotype)
Trial: 27878892
Drug: SIGLEC9 rs2075803
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SIGLEC9 rs2075803 G/rs2258983 A haplotype
Trial: 27878906
Drug: simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simeprevir 150 mg, daclatasvir 60 mg and sofosbuvir 400 mg, once daily for 12 weeks
Trial: 27879486
Drug: Tenofovir administered
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tenofovir administered from week 28 of pregnancy until delivery
Trial: 27879972
Drug: REGN2810 (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: REGN2810 (anti-PD-1 monoclonal antibody)
Trial: 27881039
Drug: Fludarabine, cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine, cyclophosphamide, and lenalidomide (starting dose 2.5 mg, maximum tolerated dose 5 mg)
Trial: 27881569
Drug: Extended-duration oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-duration oral betrixaban (80 mg once daily for 35-42 days)
Trial: 27881569
Drug: Standard-dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose subcutaneous enoxaparin (40 mg once daily for 10±4 days)
Trial: 27882104
Drug: Mesenchymal stem
RxNorm normalized name: Human mesenchymal stem cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mesenchymal stem cell (MSC) infusion derived from human umbilical cord
Trial: 27883166
Drug: Low-dose rapamycin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose rapamycin (0.5mg, 1.0mg, 2mg daily for 12 weeks)
Trial: 27883239
Drug: Omalizumab (individualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (individualized dosing)
Trial: 27883239
Drug: Omalizumab (elevated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (elevated dose)
Trial: 27883239
Drug: Omalizumab (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omalizumab (normal dose)
Trial: 27883297
Drug: Rotigotine transdermal
RxNorm normalized name: Rotigotine Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rotigotine transdermal patch (maintenance dose)
Trial: 27884140
Drug: Cisplatin (on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin (on day 1, every 3 weeks) and cetuximab (on day 1, weekly), in combination with oral valproic acid (VPA) given daily from day -14 with a target serum level of 50-100 μg/ml.
Trial: 27884766
Drug: GSK2256294 (18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256294 (18 mg)
Trial: 27887632
Drug: Sorafenib (antiangiogenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (antiangiogenic drug)
Trial: 27887660
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized peripheral blood stem cells (PBSC)
Trial: 27887660
Drug: Co-infusion of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-infusion of haplo-identical donor-derived CD19-directed CAR-T cells and mobilized PBSC
Trial: 27890073
Drug: Nilotinib 400
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg twice per day
Trial: 27890073
Drug: Imatinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 600 mg once per day
Trial: 27890073
Drug: Nilotinib 400
RxNorm normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nilotinib 400 mg twice per day (excluding crossover responses)
Trial: 27890073
Drug: Imatinib 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 600 mg once per day (excluding crossover responses)
Trial: 27890471
Drug: Riociguat (0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (0.5-2.5 mg TID) during a 10-week titration phase and a 14-week maintenance phase
Trial: 27890471
Drug: Riociguat (0.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (0.5-2.5 mg TID)
Trial: 27890936
Drug: Imatinib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib treatment cessation
Trial: 27891230
Drug: Prucalopride 0.02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 0.02 mg/kg
Trial: 27891230
Drug: Prucalopride 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 0.04 mg/kg
Trial: 27891230
Drug: Prucalopride 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prucalopride 0.06 mg/kg
Trial: 27895003
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein supplementation (1.2 g/kg IBW per day)
Trial: 27895003
Drug: Standard protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protein supplementation (0.8 g/kg IBW per day)
Trial: 27895279
Drug: Immunoglobulin G
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin G (IgG) responses to malaria
Trial: 27896545
Drug: Pasireotide long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide long-acting release 40 mg administered intramuscularly every 28 days
Trial: 27896822
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg once-daily plus Sofosbuvir 400 mg once-daily for 12 weeks
Trial: 27896822
Drug: Simeprevir plus
RxNorm normalized name: Simeprevir
DrugBank: Simeprevir (DB06290)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Simeprevir plus Sofosbuvir treatment
Trial: 27900346
Drug: ZFN-mediated CCR5
RxNorm normalized name: Mcla-128 (igg1 bispecific antibody with enhanced antibody-dependent cell-mediated cytotoxicity (adcc) activity targeting her2 and her3 receptors.)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZFN-mediated CCR5 disruption in HSPC; specific dosage and duration not mentioned.
Trial: 27900346
Drug: Allogeneic stem
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic stem cell transplantation with naturally occurring homozygous deletion of CCR5 in donor HSPC; specific dosage and duration not mentioned.
Trial: 27900579
Drug: AhR agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AhR agonist treatment
Trial: 27903416
Drug: JE-CV (live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV (live attenuated Japanese encephalitis vaccine) administered as primary vaccination (Group 1)
Trial: 27903416
Drug: JE-CV (live
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JE-CV (live attenuated Japanese encephalitis vaccine) administered as booster vaccination (Group 2)
Trial: 27903616
Drug: hs-TnI cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hs-TnI cutoff of 3 ng/L with low risk ECG
Trial: 27904903
Drug: eGFR <45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eGFR <45 ml/min/1.73 m²
Trial: 27904904
Drug: N8-GP for
RxNorm normalized name: N8-GP
DrugBank: Turoctocog alfa pegol (DB14738)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: N8-GP for on-demand treatment (20-75 IU/kg)
Trial: 27906044
Drug: Dense breasts
RxNorm normalized name: chicken breast preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dense breasts (>50% density) with positive margin, no adjuvant radiotherapy, and no adjuvant chemotherapy
Trial: 27908594
Drug: Rucaparib (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rucaparib (600 mg twice per day for continuous 28 day cycles)
Trial: 27908843
Drug: Telemedically-delegated medication
RxNorm normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedically-delegated medication by paramedics (study group)
Trial: 27911128
Drug: Docetaxel in
RxNorm normalized name: docetaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel in combination with oxaliplatin and S-1 (DOS2w)
Trial: 27911128
Drug: Docetaxel in
RxNorm normalized name: docetaxel Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel in combination with oxaliplatin and S-1 (DOS3w)
Trial: 27911591
Drug: Gonadotropin-releasing hormone
RxNorm normalized name: Gonadotropin-releasing hormone
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gonadotropin-releasing hormone (GnRH) analog treatment
Trial: 27912069
Drug: Inactivated quadrivalent
RxNorm normalized name: influenza virus vaccine, inactivated quadrivalent intramuscular suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated quadrivalent influenza vaccine (Fluarix™ Tetra)
Trial: 27912784
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg/day) added to metformin (1500-3000 mg/day)
Trial: 27913777
Drug: Ultrasound-facilitated, catheter-directed,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-facilitated, catheter-directed, low-dose fibrinolysis
Trial: 27913881
Drug: S-1 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 plus oral leucovorin (S-1/LV)
Trial: 27914133
Drug: Lobeglitazone 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lobeglitazone 0.5 mg once daily for 24 weeks
Trial: 27914971
Drug: Ofatumumab 300
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 300 mg during week 1 followed by 1000 mg during weeks 2-4 (Group A)
Trial: 27914971
Drug: Ofatumumab 300
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Group B)
Trial: 27914971
Drug: Ofatumumab 300
RxNorm normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ofatumumab 300 mg during week 1 and 2000 mg during weeks 2-5 (Cycle 2 for responders)
Trial: 27915457
Drug: Pharmacist-led intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-led intervention using the RASP list and medication review
Trial: 27918881
Drug: QUIT4EVER (mobile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUIT4EVER (mobile contingency management smoking cessation counseling and medications + Stay Quit Coach)
Trial: 29143565
Drug: Darunavir 800
RxNorm normalized name: darunavir 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir 800 mg once daily (QD)
Trial: 27919899
Drug: Darunavir 600
RxNorm normalized name: darunavir 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir 600 mg twice daily (BID)
Trial: 27919899
Drug: Three-direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-direct-acting antiviral (3D) regimen with ribavirin (RBV)
Trial: 27921340
Drug: Exposure therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure therapy (speech exposure session)
Trial: 27923043
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg daily until progression
Trial: 27923043
Drug: Afatinib 40
RxNorm normalized name: afatinib 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib 40 mg daily and intravenous vinorelbine 25 mg/m2 weekly after progression
Trial: 27923359
Drug: Sertraline (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (doses ranged from 12.5 to 150 mg/day, mostly 25 and 50 mg/day)
Trial: 27926979
Drug: Erythropoiesis-stimulating agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agents (ESAs), median duration of 27.5 months (range 0-77 months)
Trial: 27927586
Drug: RBAC500 (rituximab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBAC500 (rituximab 375 mg/m2, bendamustine, low-dose cytarabine)
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake of 200-249 μg/d for children aged 7-10 y
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake of 250-299 μg/d for children aged 11-14 y
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake ≥150 μg/d
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake ≥250 μg/d for children aged 7-10 y
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake ≥300 μg/d for children aged 11-14 y
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake of 150-249 μg/d for children aged 7-10 y
Trial: 27927635
Drug: Iodine intake
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine intake of 150-299 μg/d for children aged 11-14 y
Trial: 27927766
Drug: Rebastinib (DCC-2036)
RxNorm normalized name: Rebastinib
DrugBank: Rebastinib (DB13005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rebastinib (DCC-2036) administered at doses from 57 mg to 1200 mg daily (powder-in-capsule) and 100 mg to 400 mg daily (tablet preparations). Maximum tolerated dose was 150 mg tablets administered twice daily.
Trial: 27928641
Drug: Severe dental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Severe dental conditions (poor oral hygiene)
Trial: 27928738
Drug: Clarithromycin 1000
RxNorm normalized name: clarithromycin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 1000 mg
Trial: 27930357
Drug: High adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High adenosine dose (200 μg/kg per minute)
Trial: 27930357
Drug: Standard adenosine
RxNorm normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard adenosine dose (140 μg/kg per minute)
Trial: 27931243
Drug: Pacritinib 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib 400 mg QD
Trial: 27931243
Drug: Pacritinib 100
RxNorm normalized name: pacritinib 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib 100 to 600 mg QD
Trial: 27931243
Drug: Pacritinib 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pacritinib 500 mg QD